RIGL
HealthcareRigel Pharmaceuticals, Inc.
$41.19
$-0.64 (-1.53%)
Jan 5, 2026
Price History (1Y)
Analysis
Rigel Pharmaceuticals, Inc. is a biotechnology company operating in the healthcare sector. With a market capitalization of $747.65 million and annual revenues of $282.08 million, the company has a notable presence in its industry. Rigel employs 162 individuals. The company's financial health appears robust, with a gross margin of 83.1%, an operating margin of 40.9%, and a profit margin of 40.2%. Returns on equity and assets stand at 220.1% and 38.9%, respectively. The balance sheet indicates a cash position of $137.14 million and debt of $60.88 million, resulting in a debt-to-equity ratio of 51.77. The company's valuation is supported by a price-to-earnings (P/E) ratio of 6.75 on a trailing basis and a forward P/E of 9.49. Revenue growth has been significant, with a year-over-year increase of 25.6%, while earnings growth has been even more pronounced at 108.6%.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Rigel Pharmaceuticals, Inc.
Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), as well as to treat adult and pediatric patients twelve years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral interleukin receptor-associated kinases 1 and 4 (IRAK1/4) inhibitor for the treatment of hematology-oncology, autoimmune, and inflammatory diseases, as well as to treat lower-risk myelodysplastic syndrome. In addition, the company has product candidates in clinical development with partners BerGenBio ASA, Eli Lilly and Company, and Daiichi Sankyo. It has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of Olutasidenib in AML and other hematologic cancers with IDH1mutations, as well as with collaborative network for neuro-oncology clinical trials to evaluate Olutasidenib in combination with temozolomide in patients with high-grade glioma harboring an IDH1 mutation. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.
Visit website →Key Statistics
- Market Cap
- $747.65M
- P/E Ratio
- 6.75
- 52-Week High
- $52.24
- 52-Week Low
- $15.50
- Avg Volume
- 610.91K
- Beta
- 1.11
Company Info
- Industry
- Biotechnology
- Exchange
- NMS
- Country
- United States
- Employees
- 162